Gamida Cell Ltd. (GMDA) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Gamida Cell Ltd. (GMDA) Misses Q2 EPS by 2c

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

August 15, 2022 7:00 AM EDT

- Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date set for January 30, 2023 -

- Dosed first patient in company-sponsored Phase 1/2 study of cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas -

- Finished second quarter of 2022 with $55.1 million in cash;

sufficient funding for the companys operations into mid-2023, excluding the cost of commercializing omidubicel -

- Company to host conference call at 8:00 a.m. ET... More